8-K: Aptose Reschedules Shareholder Meeting for Hanmi Acquisition

Aptose Biosciences has rescheduled its special shareholder meeting to approve the acquisition by Hanmi Pharmaceutical Co. Ltd., pending final SEC proxy statement clearance.

Summary

• Aptose Biosciences Inc. announced the rescheduling of its special meeting of shareholders, originally set for January 16, 2026, to a later date in January 2026.
• The delay is due to pending final clearance of the proxy statement from the United States Securities and Exchange Commission (SEC).
• No changes are expected to the record date of December 12, 2025, or to the matters to be put before shareholders.
• The matters include the continuance of Aptose from the Canada Business Corporations Act to the Business Corporations Act (Alberta) (ABCA) and the subsequent acquisition by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., via a statutory plan of arrangement under the ABCA.
• Aptose's board of directors unanimously recommends that shareholders vote FOR the special resolutions approving the Continuance and the Arrangement.
• An interim order from the Court of Kings Bench of Alberta was obtained on December 12, 2025, authorizing the holding and conduct of the Meeting.
• The proxy statement, form of proxy, letter of transmittal, and additional required disclosure will be mailed to shareholders and made available on SEDAR+ and EDGAR following SEC clearance.

Sentiment

Score: 7

Explanation: The core event, an acquisition by Hanmi Pharmaceutical, is a significant positive for Aptose. While the delay in the shareholder meeting introduces a minor element of uncertainty, it is procedural (pending SEC clearance) and the board's unanimous recommendation for the transaction maintains a generally positive outlook.

Positives

• The acquisition by Hanmi Pharmaceutical Co. Ltd. is progressing, indicating a potential exit for shareholders.
• Aptose's board of directors unanimously recommends the transaction, suggesting strong internal support.
• An interim order from the Court of Kings Bench of Alberta has been obtained, a necessary legal step for the transaction.

Negatives

• The special shareholder meeting has been delayed, introducing uncertainty regarding the exact new date.
• The transaction remains subject to various approvals, including regulatory, shareholder, and Court clearances, which could still fail.

Risks

• The Transaction may not be completed on the terms and conditions, or on the timing, currently contemplated, or at all, due to failure to obtain or satisfy required regulatory, shareholder, and Court approvals.
• There is a risk that competing offers or acquisition proposals could be made.
• Failure to complete the Transaction for any reason could negatively impact the price of Aptose common shares or the business of Aptose.
• Hanmi Purchasers may fail to pay the cash consideration at completion of the Transaction.
• Aptose's business may experience significant disruptions, including loss of employees due to transaction-related uncertainty, industry conditions, or other factors.
• Risks related to employee retention exist.
• Regulatory changes may materially impact the business or operations of Aptose.
• Management's attention may be diverted from Aptose's ongoing business operations while the Transaction is pending.
• Other risks and uncertainties affecting Aptose, including those described in filings and reports Aptose may make from time to time with Canadian securities authorities.

Future Outlook

The rescheduled Special Meeting is expected to be held as soon as practicable in January 2026, following final SEC clearance of the proxy statement. Aptose intends to mail all necessary proxy materials to shareholders after this clearance. The completion of the acquisition by Hanmi Purchasers remains contingent on regulatory, shareholder, and Court approvals.

Management Comments

• Aptose has determined to reschedule the Meeting after it receives final clearance of the proxy statement from the United States Securities and Exchange Commission (SEC).
• The Company's board of directors unanimously recommends that the holders of Aptose common shares vote FOR the special resolutions approving the Continuance and the Arrangement at the Meeting.

Industry Context

Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly hematology with its lead compound tuspetinib for AML. The acquisition by Hanmi Pharmaceutical Co. Ltd. represents a strategic move within the biotechnology sector, potentially allowing Hanmi to expand its pipeline or market presence, while providing Aptose with resources and a defined path forward for its drug development programs.

Corporate Governance

Legal Proceedings

• Aptose obtained an interim order from the Court of Kings Bench of Alberta on December 12, 2025, authorizing the holding and matters relating to the conduct of the Special Meeting.

Stakeholder Impact

• Shareholders: Will vote on the proposed acquisition and continuance; potential to receive cash consideration upon transaction completion; subject to risks of delay or non-completion.
• Employees: Face potential disruptions and risks related to retention due to transaction-related uncertainty.
• Management: Attention may be diverted from ongoing business operations while the acquisition is pending.

Next Steps

• Aptose to receive final clearance of the proxy statement from the SEC.
• Aptose to announce the new date, time, and virtual details for the rescheduled Special Meeting.
• Aptose to mail the proxy statement, form of proxy, letter of transmittal, and additional required disclosure to shareholders.
• Shareholders to vote on the Continuance and the Arrangement at the rescheduled meeting.
• Completion of the acquisition by Hanmi Purchasers, subject to all necessary approvals.

Key Dates

Recommendation

The filing details a procedural delay in a previously announced acquisition by Hanmi Pharmaceutical, which is a significant corporate event. The board's unanimous recommendation for the transaction, coupled with the procedural nature of the delay (SEC clearance), suggests the acquisition is still on track. For existing shareholders, holding the stock is advisable to realize the acquisition premium. For new investors, the upside may be limited as the current price likely reflects much of the acquisition value, while residual risks of non-completion, though diminished, still exist.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Acquisition, Merger, Shareholder Meeting, SEC Clearance, Biotechnology, Oncology, AML, Tuspetinib, Corporate Governance